8
Participants
Start Date
July 17, 2025
Primary Completion Date
December 15, 2025
Study Completion Date
January 31, 2026
Onabotulinum Toxin Type A - Phase 1b
The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 50 units per patient.
Onabotulinum Toxin Type A - Phase 2
The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 75 units per patient.
NOT_YET_RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
RECRUITING
UPMC Department of Dermatology, Pittsburgh
Collaborators (1)
Almirall, S.A.
INDUSTRY
Daniel Kaplan
OTHER